Aura Biosciences, a portfolio company of Spanish biotechnology venture capital firm Ysios Capital, has priced its initial public offering (IPO) and is trading on the Nasdaq Global Market (NASDAQ: AURA).
Aura Biosciences, a portfolio company of Spanish biotechnology venture capital firm Ysios Capital, has priced its initial public offering (IPO) and is trading on the Nasdaq Global Market (NASDAQ: AURA).
This is the third Ysios Capital portfolio company, alongside LAVA Therapeutics (NASDAQ: LVTX) and CVRx Inc (NASDAQ: CVRX), to list on NASDAQ this year.
Aura Biosciences Inc announced the pricing of 5,400,000 shares of common stock at a public offering price of USD14.00 per share. In addition, Aura has granted the underwriters a 30-day option to purchase up to an additional 810,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. All of the shares are being offered by Aura.
Ysios Capital has been supporting the company since its early days through its active role on the board and has contributed to the company’s growth and progress. In line with Ysios’s investment strategy to support companies over their life cycle as they reach value inflection points, Ysios has also participated in the company’s more recent financing rounds.
Joël Jean-Mairet, Managing Partner at Ysios Capital and responsible for the investment in Aura, says: “At Ysios Capital we support exceptional teams with pioneering science and the drive to change patients’ lives. Aura is clearly an example of a pioneering company led by an outstanding team, with top-notch international investors and the potential for a positive impact on patients and society. We believe Aura’s technology is uniquely positioned to enable the development of therapies for cancers that currently have no effective treatments.”
The shares began trading on the Nasdaq Global Select Market on 29 October, 2021, under the ticker symbol “AURA.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aura, are expected to be USD75.6 million.
